What Is New - Pediatric Rheumatological Conditions

Take a look at our 'What is new' highlights in pediatric rheumatology!

February 2023

"Validity Of Ultrasonography In Detecting Enthesitis In Children: A Systematic Literature Review"

Why WINS?

Because of the peculiarities of the growing skeleton, consensual definitions and a scoring system for enthesitis in JIA are essential.

Do you routinely carry out US for enthesitis in JIA patients?

Yes, for diagnostic purposes
Yes, for diagnosis and follow-up
Not at all

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

Jan 2023

"Aberrant naive CD4+ T cell differentiation in systemic juvenile idiopathic arthritis is committed to B cell help"

Why WINS?

This study contributes to the understanding of sJIA pathogenesis, suggesting a role of adaptive immune cells, namely Tf/ph cells in disease, in line with the biphasic model of disease progression.

Do you think that interfering with Tf/ph polarization by interrupting IL-21 signaling could be a viable strategy in sJIA?

yes or no?

Share your response with us using the hashtag #WhatIsNew and tag us @EMEUNET

May 2022

" The pediatric glucocorticoid toxicity index "

Why WINS?

Glucocorticoids (GC) have wide variety of side effects and it is even more difficult to measure this in pediatric patients given that there is age impact on different toxicity profiles. There is no widely used composite measure to understand the GC toxicity in peaditric population. This study provides the development and first evaluation of pediatric GC toxicity index.

Interactive question

What will be the main purpose to use pgTI for you?

1. To understand steroid sparing effect of drugs in clinical trials
2. To understand the toxicity of GCs in clinical practice
3. both

Join the discussion on twitter... Share your response with us using the hastag #WhatIsNew and tag us @EMEUNET

May 2022

"Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA"

Why WINS?

This large analysis of real-world data, including >8000 children and young people with JIA, identified that the risk of new onset TNF inhibitor-associated psoriasis was ~5.6 times higher (adjusted for methotrexate, sex, race, family history of psoriasis, and ILAR) in those with non-psoriatic arthritis compared with those not treated with TNF inhibitors.

Interactive question

Would you be more likely to report new-onset psoriasis in JIA for those on TNFi – could this higher rate be influenced by reporting bias?

yes/no

Join the discussion on twitter... Share your response with us using the hastag #WhatIsNew and tag us @EMEUNET